» Articles » PMID: 20213835

Enhancement of Transdermal Absorption, Gene Expression and Stability of Tyrosinase Plasmid (pMEL34)-loaded Elastic Cationic Niosomes: Potential Application in Vitiligo Treatment

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2010 Mar 10
PMID 20213835
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The pMEL34 was loaded in elastic cationic niosomes (Tween61/Cholesterol/DDAB at 1:1:0.5 molar ratio) by chloroform film method with sonication and rehydrated with 25% ethanol. The amount of pMEL34 was determined by gel electrophoresis and gel documentation. The maximum loading of pMEL34 in elastic cationic niosomes was 150 microg/16 mg of the niosomal compositions. At 8 weeks, the remaining plasmid in the elastic niosomes kept at 4 +/- 2 degrees C, 27 +/- 2 degrees C were 49.75% and 38.57%, respectively, whereas at 45 +/- 2 degrees C, all plasmids were degraded. For transdermal absorption through rat skin investigated by Franz diffusion cells at 6 h, the fluxes of pMEL34 loaded in elastic and nonelastic niosomes in viable epidermis and dermis (VED) were 0.022 +/- 0.00 and 0.017 +/- 0.01 microg/cm(2)/h, respectively, whereas only pMEL34 loaded in elastic cationic noisome was observed in the receiver solution. The pMEL34 loaded in elastic cationic niosomes showed the highest tyrosinase gene expression demonstrating higher tyrosinase activity than the free and the loaded plasmid in nonelastic niosomes of about four times. This study has suggested the potential application of elastic cationic niosomes as an efficient topical delivery for tyrosinase gene in vitiligo therapy.

Citing Articles

Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications.

Akombaetwa N, Ilangala A, Thom L, Memvanga P, Witika B, Buya A Pharmaceutics. 2023; 15(2).

PMID: 36839978 PMC: 9967415. DOI: 10.3390/pharmaceutics15020656.


Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines.

Bolhassani A Mol Biotechnol. 2022; 65(5):669-698.

PMID: 36462102 PMC: 9734811. DOI: 10.1007/s12033-022-00624-8.


Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.

Tang J, Cai L, Xu C, Sun S, Liu Y, Rosenecker J Nanomaterials (Basel). 2022; 12(2).

PMID: 35055244 PMC: 8777913. DOI: 10.3390/nano12020226.


Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo.

Sun M, Xu X, Lou X, Du Y Int J Nanomedicine. 2020; 15:3267-3279.

PMID: 32440123 PMC: 7217315. DOI: 10.2147/IJN.S245326.


Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery.

Ge X, Wei M, He S, Yuan W Pharmaceutics. 2019; 11(2).

PMID: 30700021 PMC: 6410054. DOI: 10.3390/pharmaceutics11020055.